Back to results
US 12,545,719 B2Granted
Neutralizing antibodies to GP120 and their use
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsMark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
Claims19
An isolated monoclonal antibody, comprising:
- a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 set forth as SEQ ID NOs:
- 7, 8, and 9, respectively;
- a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3 set forth as SEQ ID NOs:
- 10, 11, and 12, respectively;
- and
- an IgG constant domain comprising a modification that increases antibody dependent cellular cytotoxicity (ADCC) relative to an unmodified IgG constant domain, wherein the modification comprises defucosylation of the IgG constant domain,
- wherein the isolated monoclonal antibody specifically binds to HIV-1 gp120 and neutralizes HIV-1.
4 more elements
Dependencies are inferred from the claim text.